• Loading stock data…

LEO Pharma Announces FDA Approval of Adbry™ (tralokinumab) as the First and Only Treatment Specifically Targeting IL-13 for Adults With Moderate-to-Severe Atopic Dermatitis

[#item_full_content]

Print Friendly, PDF & Email
Spread the word